UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 718, 2025

Vaccinex, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-38624	16-1603202
(State or other jurisdictionof incorporation)	(CommissionFile Number)	(IRS EmployerIdentification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
1895 Mount Hope Avenue, Rochester, New York		14620
(Address of principal executive offices)		(Zip Code)

~~Registrant’s telephone number, including area code:~~ (585) 271-2700

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~TradingSymbol~~Trading Symbol(s)		Name of each ~~exchangeon~~exchange on which registered
Common Stock, par value $0.0001 per share		VCNX		~~OTC~~Nasdaq ~~Pink~~Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 35.0102 ~~Notice~~Departure of ~~Delisting~~Directors or ~~Failure~~Certain toOfficers; ~~Satisfy~~Election aof ~~Continued~~Directors; ~~Listing~~Appointment ~~Rule~~of orCertain ~~Standard~~Officers; ~~Transfer~~Compensatory Arrangements of ~~Listing~~Certain Officers.

On March 718, 2025, Bala S. Manian informed Vaccinex, Inc. (the “Company”), ~~notified~~of ~~the~~his ~~Nasdaq~~resignation ~~Stock~~as ~~Market~~a ~~(“Nasdaq”)~~director of the Company’s ~~intention~~effective ~~to delist its shares of common stock, par value $0~~immediately.~~0001~~ ~~per share (the “Common Stock”), from Nasdaq~~Mr. Manian’s ~~The~~departure ~~Company~~was ~~intends~~not due to ~~file~~any adisagreement ~~Form 25~~ with the ~~Securities~~Company ~~and Exchange Commission~~ on orany ~~about~~matter ~~March 17,~~relating ~~2025,~~ to ~~delist~~ the ~~Common~~Company’s ~~Stock.~~operations, ~~Trading~~policies inor ~~the Common Stock on Nasdaq has been suspended since December 18, 2024~~practices.

Item 7.01 Regulation FD Disclosure.

On March 7, 2025, the Company issued a press release announcing its intention to voluntarily delist the Common Stock from Nasdaq. A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

The following exhibits are furnished herewith:

ExhibitNumber		Exhibit Description
99.1		Press release, dated March 7, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the ~~Registrant~~registrant has duly caused this ~~Report~~report to be signed on its behalf by the undersigned hereunto duly authorized.

	Vaccinex, Inc.
		VACCINEX, INC.
Date: March 7, 2025	By:	/s/ Maurice Zauderer
Date: March 19, 2025
		Maurice Zauderer
	By:	/s/ Jill Sanchez
		Chief Executive Officer
		Jill Sanchez
		Chief Financial Officer

Filing Compare · VACCINEX, INC.